ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Introducing ALK Positive UK: Founded by Debra Montague
Debra Montague was diagnosed in October 2016 and joined the world-wide ALK Positive Facebook support group. She came to realise that there was a need for a UK group to address issues that are specific to UK patients, e.g. the National Health Service, the Driving Licence Regulator and the Drugs Approval Regulator. In July 2018,…
-
My Thoracentesis Experience
During the Thanksgiving holiday, over a liter of pleural fluid was withdrawn via needle from my right chest space. I had just finished my third cycle of Carboplatin, Pemetrexed, and Lorlatinib after almost ten years of TKIs alone. The fluid first became evident on a PET scan and was classified as moderate effusion. I didn’t…
-
My Family’s Favorite Oven-Baked Brisket: By Chef and fellow ALKie, Juli Posner
I’m sure there are a lot of people in many parts of the country that wouldn’t dream of making a brisket in the oven. But growing up in New York on Long Island, we never owned a smoker. I think once you try this virtually fuss-free, oven-baked method, you will be sold by how delicious…
-
Amanda Bialack-Stewart
Amanda has been actively involved in ALK Positive, Inc. through creating and leading the Young ALKies Group. We interviewed her in Los Angeles, California about having been diagnosed right after giving birth to twins at the age of 36, how she manages to balance family, work, fun, and self-care as a patient.
-
Amivantamab With Tyrosine Kinase Inhibitors (TKIs) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Who is this trial for: This trial is for patients with one of three forms of non-small cell lung cancer (NSCLC) – ALK, ROS1, or RET – who are progressing on their current TKI under certain conditions, and are willing to try an experimental drug combination in order to extend the life of their current…
-
Rich Gopen
Rich Gopen is an ALK patient and one of our match donors for Lung Cancer Awareness Month (LCAM). We interviewed Rich about his journey with ALK+ lung cancer, what motivates him, and his hopes for the future.
-
Phase II Clinical Trial NCT05384626 by Nuvalent, Inc. A Study of NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
ALKOVE-1 Study Results Summary: NVL-655’s Promising Role in Treating Advanced ALK+ Lung Cancer
The clinical results from the Phase 1 portion of the ALKOVE-1 study is bringing new hope to patients with ALK-positive lung cancer, especially those who have exhausted other treatment options. NVL-655, a fourth-generation ALK inhibitor, has shown unique effectiveness in overcoming resistance to previous treatments, including those with brain metastases and specific resistance mutations
-
Introducing ALKpositiv Deutschland (Germany) An interview with Sabine Hatzfeld & Nicoline Ehrhardt
In recent years, the German patient network, ALKpositiv Deutschland, has become an important point of contact for patients with ALK-positive lung cancer in German-speaking countries. Our story began in 2019 with a Facebook group that served as a platform for those affected to exchange information. From the outset, this group was an important place to…
-
MEET YOUR STAFF: Introducing Sadia Yaakov, Medical Project Manager at ALK Positive, Inc
I was born and raised in Pennsylvania and had an interest in cancer research from the time that I was a child. I was exposed to Fox Chase Cancer Center very early on and knew from that moment that I wanted to do something to help in the fight against cancer. I attended University of…
-
Palliative Care for ALK-Positive Lung Cancer: Research Identifies a Vital Resource for Improving Quality of Life
For individuals diagnosed with ALK-positive lung cancer, the mention of palliative care can often lead to confusion or misunderstanding. Many wonder: Why is palliative care recommended? How does it fit into my treatment plan? Do I need it now, or is it something to consider later? Let’s look at the research and explore how palliative…
-
MEET YOUR STAFF: Introducing Katie Delaney, Philanthropy Operations Manager at ALK Positive, Inc.
With over a decade of entrepreneurship and management experience, I’ve learned one enduring truth: obstacles become opportunities when met with hard work and dedication. Believing that anything is possible with perseverance and self-belief, I’ve discovered that the greatest gift is empowering others to believe in themselves as well.